Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.
An article from
Dive Brief
//
Vaccines
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Three vaccine biotechs to be bought by Lilly for up to $3.8B
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Eli Lilly acquires three vaccine developers for $3.8 billion
Eli Lilly to buy three small vaccine developers
Eli Lilly spending $3.8 billion to buy vaccine makers
What's Going On With Eli Lilly Stock Tuesday? - Eli Lilly (NYSE:LLY)
Eli Lilly comprará 3 empresas fabricantes de vacunas por casi 4 mil mdd; ampliará investigación de enfermedades infecciosas | El Universal
Eli Lilly maintains M&A streak with $202m Engage Bio buyout - Pharmaceutical Technology
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious…
Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling…
Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss…
Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.
